Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Colorcon
Medtronic
McKinsey
McKesson
Johnson and Johnson
AstraZeneca

Last Updated: October 20, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR VELTASSA

See Plans and Pricing

« Back to Dashboard

Clinical Trials for Veltassa

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00868439 Evaluation of Patiromer in Heart Failure Patients Completed Medpace, Inc. Phase 2 2009-04-01 The purpose of this study was to assess the effects of patiromer on serum potassium participants with heart failure. This study also assessed the safety and tolerability of patiromer in participants with heart failure.
NCT00868439 Evaluation of Patiromer in Heart Failure Patients Completed Relypsa, Inc. Phase 2 2009-04-01 The purpose of this study was to assess the effects of patiromer on serum potassium participants with heart failure. This study also assessed the safety and tolerability of patiromer in participants with heart failure.
NCT01130597 Evaluation of Patiromer Titration in Heart Failure Patients With Chronic Kidney Disease Completed Relypsa, Inc. Phase 2 2010-05-01 The purpose of this study was to evaluate the feasibility of individualized titration of patiromer according to serum potassium. This study also assessed the safety and tolerability of patiromer and the effects of patiromer on serum potassium in heart failure (HF) participants with chronic kidney disease (CKD).
NCT01371747 Patiromer in the Treatment of Hyperkalemia in Patients With Hypertension and Diabetic Nephropathy (AMETHYST-DN) Completed Relypsa, Inc. Phase 2 2011-06-01 This study determined the optimal starting dose of patiromer in treating hyperkalemia in participants with hypertension and diabetic nephropathy who were already receiving ACEI and/or ARB drugs, with or without spironolactone. This study also evaluated the efficacy and safety of patiromer and the long term use of patiromer.
NCT01810939 A Two-Part, Single-Blind, Phase 3 Study Evaluating the Efficacy and Safety of Patiromer for the Treatment of Hyperkalemia (OPAL) Completed Relypsa, Inc. Phase 3 2013-02-01 The purpose of this study was to evaluate the efficacy and safety of patiromer (investigational drug) in the treatment of hyperkalemia (high serum potassium). The study also evaluated the effect of withdrawing patiromer treatment and assessed whether chronic treatment with patiromer prevented the recurrence of hyperkalemia. The safety of patiromer treatment was also evaluated.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Veltassa

Condition Name

Condition Name for Veltassa
Intervention Trials
Hyperkalemia 9
Heart Failure 2
Hypertension 1
Hyperkalemia (HK) 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Veltassa
Intervention Trials
Hyperkalemia 10
Kidney Diseases 6
Renal Insufficiency, Chronic 6
Heart Failure 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Veltassa

Trials by Country

Trials by Country for Veltassa
Location Trials
United States 49
Georgia 6
Ukraine 4
Slovenia 3
Serbia 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Veltassa
Location Trials
Florida 5
Texas 5
California 4
New York 4
Michigan 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Veltassa

Clinical Trial Phase

Clinical Trial Phase for Veltassa
Clinical Trial Phase Trials
Phase 4 2
Phase 3 2
Phase 2 6
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Veltassa
Clinical Trial Phase Trials
Completed 5
Recruiting 3
Not yet recruiting 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Veltassa

Sponsor Name

Sponsor Name for Veltassa
Sponsor Trials
Relypsa, Inc. 10
New York University School of Medicine 1
Medpace, Inc. 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Veltassa
Sponsor Trials
Industry 12
Other 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Boehringer Ingelheim
Express Scripts
Baxter
McKesson
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.